An anticonvulsant drug called gabapentin is primarily employed to treat neuropathic pain and partial seizures. It is a first-line treatment for central pain, postherpetic neuralgia, and neuropathic ...

Gabapentin Market Size to Hit USD 3.55 Billion by 2032, Driven by Rising Cases of Epilepsy, Neuropathic Pain, and Off-Label Use – SNS Insider. ... By Dosage Form: Capsule Dominate Market.

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin tablets, 600 mg and 800 mg, of Viatris Specialty LLC. Gabapentin tablets has a market size of ...

MENLO PARK, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that US FDA has approved GRALISE™ (gabapentin) Tablets for once-daily treatment of post-herpetic ...

Indian drugmaker Ranbaxy Laboratories Ltd <RANB.BO> is recalling some gabapentin tablets in the United States, a spokesman said, confirming a report in the Economic Times on Friday.

Lupin has received approval from the US health regulator to market its generic Gabapentin tablets used for the treatment of postherpetic neuralgia in the American market. According to a company ...

The annual sales of Gabapentin Tablets (Once-Daily), 300 mg, and 600 mg, in the United States, were recorded at $85 million in November 2023, according to IQVIA.